Chemical Proteomics Reveals Antibiotic Targets of Oxadiazolones in MRSA

  • J Am Chem Soc. 2023 Jan 18;145(2):1136-1143. doi: 10.1021/jacs.2c10819.
Alexander T Bakker  1 ,  Ioli Kotsogianni  2 ,  Liza Mirenda  1 ,  Verena M Straub  1 ,  Mariana Avalos  3 ,  Richard J B H N van den Berg  1 ,  Bogdan I Florea  1 ,  Gilles P van Wezel  3 ,  Antonius P A Janssen  1 ,  Nathaniel I Martin  2 ,  Mario van der Stelt  1
Affiliations
  • 1. Department of Molecular Physiology, Leiden Institute of Chemistry, Leiden University, Leiden 2300 RA, The Netherlands.
  • 2. Biological Chemistry Group, Institute of Biology Leiden, Leiden University, Leiden 2333 BE, The Netherlands.
  • 3. Department of Molecular Biotechnology, Institute of Biology Leiden, Leiden University, Leiden 2333 BE, The Netherlands.
PMID: 36584241 DOI: 10.1021/jacs.2c10819
Abstract

Phenotypic screening is a powerful approach to identify novel Antibiotics, but elucidation of the targets responsible for the antimicrobial activity is often challenging in the case of compounds with a polypharmacological mode of action. Here, we show that activity-based protein profiling maps the target interaction landscape of a series of 1,3,4-oxadiazole-3-ones identified in a phenotypic screen to have high Antibacterial potency against multidrug-resistant Staphylococcus aureus. In situ competitive and comparative chemical proteomics with a tailor-made activity-based probe, in combination with transposon and resistance studies, revealed several cysteine and serine hydrolases as relevant targets. Our data showcase oxadiazolones as a novel Antibacterial chemotype with a polypharmacological mode of action, in which FabH, FphC, and AdhE play a central role.

Products